• Acurx Pharmaceuticals announced published preclinical results showing its DNA pol IIIC antibiotic candidates reduced MRSA burden while preserving gut microbiome diversity.
• All three tested inhibitors reduced MRSA burden in a mouse thigh infection model.
• Compared with linezolid, the inhibitors preserved anaerobic bacterial communities and metabolic function, suggesting a potential microbiome-sparing class effect.
• Structural modifications improved solubility and systemic exposure; further structural or dosing optimization may enhance tissue-level efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77096) on October 21, 2026, and is solely responsible for the information contained therein.